PubMed Health⌕ Search

Biomedical subjects

E Simonsen

Publications and source records attributed to E Simonsen.

At least 37 records · Page 2Linked to original sources

A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients.

In a previously reported phase I study of carboplatin administered ip to patients with ovarian cancer at our clinic, it was determined that the recommended dose for phase II was 500 mg/m2. In this study, this dose was given to 47 patients with the purpose of determining the relapse-free interval and toxicity. Four courses were given with a 28-day interval in an escalated fashion. Median age of patients was 55 years. Karnofsky index was 100 in 98% of the patients. Thirty-one patients had FIGO stage I and 16 patients had FIGO stage II ovarian cancer. Median time to recurrence has not yet been reached among 43 evaluable patients after a median (range) follow-up time of 26.2 (5.5-45.9) months. Recurrent disease was documented in 10 patients (23%). The relapse site was intraabdominal in 7 and extraabdominal in 1 patient. Two patients had combined intra- and extraabdominal relapse sites. Thirty-six of 43 patients went through second-look surgery. The total number of treatment cycles given to evaluable patients was 154. In the patient group with relapsed tumor, > or = 3 courses were administered to 60%, whereas nonrelapsed patients had > or = 3 courses in 94% (P = 0.019). The reason for this distribution was higher toxicity and more frequent catheter-related problems in patients with relapsed tumor. Median (range) disease-free interval for relapsed patients was 11.5 (5.5-26.6) months. Myelosuppression, especially thrombocytopenia, was the dose-limiting systemic toxicity. The overall hematologic toxicity (all courses) was median (range) WBC 3.9(0.3-25.0) x 10(9)/liter, PLTC 212(7-961) x 10(9)/liter, and Hb 109(75-153) g/liter. WHO grade 4 toxicity for WBC was observed in 6.7%, for PLTC in 17.8%, and for Hb in 0% of the patients. Day to nadir values for WBC, PLTC, and HB were in median (cycle 1-4) 18, 16, and 18 days, respectively. Subjective toxicity was mild. In conclusion, ip carboplatin as a single-agent drug in first-line adjuvant chemotherapy of early-stage ovarian cancer has shown moderate activity. The administered dose in this study was safe, with acceptable toxicity.

Adult↗

Granulosa cell tumors of the ovary: prognostic factors and outcome.

Granulosa and theca cell tumors of the ovary account for 2-3% of ovarian malignancies. This study includes 54 patients with the diagnosis of granulosa cell tumors of the ovary treated between 1953 and 1987. Median age at diagnosis was 57 (27-83) years. The lesions were staged according to FIGO. The number of patients in various stages was IA, 41; IB, 3; IC, 3; IIB, 6; and III, 1. Median tumor size, 11 cm; range, 0.5-30 cm. Post-menopausal bleeding was diagnosed in 48%, MHC in 37%, proliferative endometrium in 32%, and atypia of endometrial cells in 13% of the cases. Fifty patients were treated with primary surgery, 48 patients were treated with adjuvant external radiotherapy, and 3 patients received complementary chemotherapy. The survival rates in stage I were 94 and 88% after 5 and 10 years, respectively, and in stages II-III were 44% after 5 and 10 years. Overall survival was 90% at 5 years. The frequency of observed mitosis influenced the survival rate: with less or equal 4/10 HPF the survival was 100% in 5 years, with 5-9/10 HPF the survival was 80% in 5 years with a median survival time of 9 years, and with more or equal 10/10 HPF the longest survival was 4 years. At the end of the study, 45 patients (83%) are alive with no evidence of disease, 1 patient is alive with disease, 4 patients are dead of recurrent disease, and 4 patients are dead from intercurrent disease. Endometrial carcinoma was detected in 5 patients. The total survival is better than that with epithelial ovarian cancer as the hormonal symptoms make an early diagnosis possible. Stage for stage the survival is equal. There is an increased incidence of endometrial carcinoma and concomitant other malignancies. The mitotic rate is a well-defined parameter and influences the survival significantly and should be considered the most important prognostic factor at treatment planning.

Abdominal Pain↗

Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer.

Peritoneal access devices (port-catheters) were subcutaneously implanted in 125 patients for intraperitoneal chemotherapy of ovarian cancer. In 98% of patients Pharmacia's Port-A-Cath was used. Four hundred sixty-five intraperitoneal courses were given to these patients, with a median of 4 courses per patient (range 0-8). The first course was given 0-60 days (median 11 days) after Port-A-Cath implantation. In 125 patients, 27 (21.6%) complications of severe or moderate degree during the treatment were registered. In 81% of the patients, the treatment was given according to chemotherapy protocol as outlined. In 7% of the patients, early termination was related to the use of Port-A-Cath and in 12% related to chemotherapy. The probability for proper functioning of Port-A-Cath was 0.74 at 6 months and 0.69 at 1 year after implantation. The mean observation time was 13.6 months, median 10.5 (range 0.3-59.6 months). Total patient access time was 141.9 years. In conclusion, the complication rate after implantation of intraperitoneal access devices is acceptable. The rate of infections associated with the system is lower than that associated with open catheter systems.

Adult↗

The borderline conditions--an introduction from a Scandinavian perspective.

There is a growing conversion, confusion and controversy in clinical psychiatry concerning the usage of the borderline concept. An increasing number of hospitalized patients are classified as borderline conditions. This expansion and popularity of the borderline concept has many explanations and historical roots: the notion of a continuum of mental disorders, the concept of forme fruste of psychotic illnesses: clinicians' uncertainty as to where to categorize some difficult patients--a nondiscriminatory synonym; the psychoanalytic establishment--and decline--in clinical psychiatry in the United States; a field for ideological battles between psychodynamic and biological oriented schools of psychiatry, etc. In ICD-10, the borderline conditions are hierarchically divided and outlined in clinical description and diagnostic guidelines into schizotypal disorder and emotionally unstable personality disorder--impulsive or borderline subcategory. This closer demarcation of prototypes in the classification system may facilitate less confusion in future. All Scandinavian countries have contributed a great deal to the research in the field of borderline conditions, especially with regard to genetic and nosological issues. A brief summary of these contributions is presented. Some important notions in the phenomenologic and prototypically oriented European tradition of classifying personality disorders are explained in order to understand the rather ambiguous reaction to the borderline concept in European countries.

Antipsychotic Agents↗

A population-based survey of ovarian malignancies in the southeast health care region of Sweden 1984-1987.

All 426 patients with ovarian malignancies registered in the population-based Tumor Registry of the Southeast region of Sweden during 1984 to 1987 were analyzed by survey of the hospital records and population registry data. After comparison with other population-based materials, it seems that the overall survival figures have improved in ovarian cancer. Excluding patients diagnosed at autopsy a 5-year corrected survival of 43% was recorded. Among patients aged under 45 years the corrected 5-year survival was 72%. In a Cox's regression analysis age and stage were significant predictors of cancer death while histology (epithelial vs. non-epithelial), although significant in the univariate analysis, did not add prognostic information in the multivariate model. The relative cancer death rate was 6.4 for patients aged over 74 years compared with those aged under 45 (p < 0.0001), and 13.8 for FIGO stage IV compared to stage I (p < 0.0001). For patients with advanced stage tumors (FIGO stage III or IV) postoperative residual tumor, stage, and age were independent prognostic factors in a multivariate analysis. The corrected cancer death rate was 2.0 for patients with > 1 cm relative to < or = 1 cm postoperative residual tumor nodule(s) (p < 0.0001).

Adolescent↗

A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer.

Between January 1, 1988 and December 31, 1990, a new high-intensity treatment was delivered to 10 patients with clinical stage I uterine papillary serous carcinoma (UPSC) and 21 patients with clinical stage I, FIGO grade 3 endometrial adenocarcinoma. The treatment consisted of a radical hysterectomy and bilateral salpingo-oophorectomy with pelvic lymph node sampling, adjuvant external pelvic radiation, and four courses of cis-platinum/epirubicin. The clinical outcome was compared to that of a historical control group treated before 1988 with surgery and radiation. None of the high-intensity treated UPSC patients died or relapsed during a median observation time of 32 months. There was a significantly better survival in the high-intensity treated UPSC group compared to the controls. The UPSC patients diagnosed after January 1, 1988 showed a trend toward better survival compared to those diagnosed before this date, whether they had received high-intensity treatment or not. No significant difference in survival was observed in the non-UPSC group subjected or not to the high-intensity treatment.

Adenocarcinoma↗

Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer.

The Swedish Tumor Registries are population based. Three hundred eighty-four patients with epithelial ovarian cancer registered in the Tumor Registry of the Southeast Health Care Region during the years 1984 to 1987 were reviewed; 332 patients were eligible for survival analysis. The protocol treatment during this period included primary surgery aimed at tumor reduction followed by combination chemotherapy (anthracyclin + cis-platinum, AP) in FIGO stages IC-IV. All patients treated otherwise were registered as prescribed nonprotocol treatment. An overall corrected 5-year survival of 40% was recorded. However, only 166/325 of the patients (51%) were actually prescribed protocol treatment as defined above. The 5-year survival was 49% for patients prescribed protocol treatment compared to 33% for those prescribed nonprotocol treatment (P < 0.0001). Stages III-IV patients prescribed protocol treatment had 23% 5-year survival compared to 11% for patients prescribed nonprotocol treatment (P < 0.0001). The impact of cis-platinum-based combination chemotherapy was thus not as pronounced as expected from clinical studies since many patients were not considered to be in a good enough general condition to receive cis-platinum. Multivariate Cox analysis of 223 cases showed that age (P < 0.0001), stage (P = 0.0002), grade of differentiation (P = 0.006), and postoperative residual tumor (P = 0.007) were independent prognostic factors. A prognostic index was developed which divided the patients into different risk groups. It was shown that high-risk patients identified by this index were mainly found in the group prescribed nonprotocol treatment and that the prognostic index could not be used to identify patients with a low probability of response among patients prescribed protocol treatment.

Adult↗

Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.

Several randomized trials of various malignancies treated with cisplatin indicate a dose-response relationship with higher MST and longer survival achieved with high-dose compared to standard dose cisplatin regimens. Thirty-five patients with stages II-IV ovarian cancer with refractory cancer at second look or recurrent disease were treated second line with intraperitoneal (ip) combination chemotherapy of high-dose cisplatin (100-200 mg/m2) plus etoposide (350 mg/m2) in 1-6 cycles. Sodium thiosulfate was given as an intravenous antidote to cisplatin. A WBC nadir < 2.0 x 10(9)/liter was registered in 39 courses and a platelet nadir < 50 x 10(9)/liter in 3 courses. Severe nephrotoxicity was observed in 2 patients. Nonhematologic and nonrenal toxicity was mild except for vomiting and nausea and alopecia. No severe neurotoxicity was observed. A total of 127 courses were administered. Total median administered dose was 960 mg and 49 mg/m2/week. Treatment was changed in 5 (14%) patients due to severe nausea and vomiting, in 4 (11%) patients due to PAC problems, and in 2 (6%) patients due to nephrotoxicity. In 4 (11%) patients the dose was reduced due to hematologic toxicity. No toxic death was recorded. Median survival time from date of diagnosis was 21.8 (mean 37.9) months and the median progression-free survival from start of ip chemotherapy was 13.7 months. For patients with MRD < or = 2 cm the MST was 18.1 months. At the closing point of this study after a median follow-up time of 16.1 (range, 4.6-55.6) months, 7 (20%) patients were alive without evidence of progression, 4 (11%) were alive with cancer, and 23 (66%) were dead of cancer and 1 (3%) was dead of intercurrent disease.

Adult↗

Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma.

Eight hundred thirty-nine clinical stage I endometrial carcinoma patients diagnosed between 1979 and 1988 were treated at the University Hospital in Linköping. Forty-two (5%) had uterine papillary serous carcinoma of which 52% died of their disease. The recurrence rate, defined as new evidence of disease 6 months or more after termination of the initial treatment, was 31% among the UPSC patients compared to 6% in the non-UPSC group. The site of recurrence also differed significantly between the two groups, with the abdomen as the most common site among UPSC patients (46%) and the vagina (34%) among the ordinary adenocarcinoma patients. All UPSC patients with recurrence died of their malignancy compared to 61% of the ordinary adenocarcinoma patients. Ninety percent of isolated vaginal recurrences in ordinary adenocarcinoma patients (17) were diagnosed at a scheduled outpatient checkup. Of these, 13 are alive with no known disease after treatment.

Adenocarcinoma↗

[Compulsory admission for treatment--an interview study of patients. 1. Admission procedure, use of restraint and treatment].

Forty-three patients committed for treatment in Copenhagen county were interviewed on their discharge from hospital. Half of the patients felt better after hospitalization, while one fourth of the patients were dissatisfied. Food, changes in housing and human contact were given as examples of the positive outcome. One half of the patients were given compulsory medication and one fourth were physically restrained. The patients experienced many adverse effects of the medication. It is recommended, that psychiatrists are involved to a higher degree in evaluation and treatment before decisions for compulsory hospitalization are taken. Investigations are needed to find predictors for a positive outcome in involuntary hospitalization. Unnecessary hospitalization should be avoided in order not to harm the patient-doctor relationship.

Adolescent↗

[Compulsory admission for treatment--an interview study of patients. 2. Rights, guardianship and attitudes to commitment].

Forty-three patients committed for treatment in Copenhagen County were interviewed about their rights, protection of rights and consequences of the commitment. Very few patients felt they had been properly informed about their rights and they knew very little about how to complain to the authorities about their commitment. Attorneys were found to have too little competence and insufficient training, and patients felt insecure about their attorneys' role. One forth of the patients agreed that they had to be committed, while one forth never accepted their commitment. Difficulties in giving information to the psychotic patient with disturbances in cognition and on unrealistic way of thinking are discussed. It is concluded, that there is a need to strengthen patients' rights, but not at the expense of the possibility of delay in administering treatment.

Adolescent↗

Flow cytometric analysis of uterine sarcoma: ploidy and S-phase rate as prognostic indicators.

Flow cytometry of various gynecological tumors has shown that aneuploid tumors and a high S-phase rate carry a prognosis worse than that of diploid tumors or tumors with a low S-phase. The aim of this study is to investigate the prognostic importance of DNA ploidy and S-phase rate in relation to mitotic count, tumor stage, tumor grade, and histology in 37 patients with uterine sarcoma stages I-IV (FIGO). Flow cytometry was performed on archival paraffin-embedded tumor tissue and the histologic specimens were reviewed by a single pathologist. Nineteen (51%) of the tumors were classified as DNA aneuploid. The S-phase fraction (SPF) was determined in 33 cases. The mean SPF (+/- SD) was 15.0% (+/- 9.5%). The mean SPF was three times higher in aneuploid tumors than in diploid cases. Both the proportion of aneuploid tumors and the mean SPF were significantly higher in later stage tumors, more poorly differentiated tumors, and tumors with a higher mitotic index. No significant differences were seen between histologic types with respect to the two cytometric variables. The 5-year cancer survival rate was only 11% in aneuploid cases compared with 59% in diploid cases (log rank, P = 0.0002). There was a significantly worse prognosis in cases with a higher SPF (P = 0.0009) and in case with a higher mitotic index (P = 0.0016). In the multivariate survival analysis using the Cox proportional hazards model, DNA ploidy showed a significant prognostic value (P = 0.046) even when adjusted for stage, grade, and mitotic index. When adjusted for stage and grade only, SPF showed significant additional prognostic value.

Adult↗

[Wernicke-Korsakoff syndrome at the Rikshospitalet in 1979-1988. A retrospective study].

Wernicke encephalopathy and Korsakoff psychosis are two facets of the same disease with well-determined cerebral lesions caused by thiamine deficiency. The disease occurs mainly in alcoholics, but other conditions (malabsorption or severe malnutrition) also predispose to the risk of Wernicke-Korsakoff syndrome. The incidence in Denmark is unknown. In the period 1.1.1979-31.12.1988, 24 patients (18 men and six women) were discharged from Rigshospitalet with the diagnosis Wernicke encephalopathy or Korsakoff psychosis. This represents about 0.05% of all admissions in the period. Eighteen out of the 24 cases (75%) were admitted in the past three years (1986-88). The mean age was 55 years. Twenty patients admitted alcohol abuse. The presenting symptoms and the patients' complaints showed great variety and were often related to other alcoholic complications, which could mask the disease. The classic symptom combination: eye movement abnormalities- ataxia and disorders of consciousness were found in seven patients (29%). Sixteen patients had disorders of consciousness or orientation. All the patients were treated with thiamine. The eye-movement disorder has recovered in eight out of ten known cases (80%), nystagmus--in six out of seven cases (86%) while ataxia, disorders of orientation and confabulation recovered in about 50% of cases. The average duration of hospitalisation was 50 days. Altogether nine patients died during the observation period. The condition is most probably underdiagnosed and the traditional diagnostic criteria are considered too rigid. The diagnosis should be considered in alcoholics who present even only one of the classical symptoms and in patients with alcohol dementia. Thiamine should be given on wide indications.

Adult↗

Angiotensin-converting enzyme inhibition as a therapeutic principle in Bartter's syndrome.

The effect of captopril has been investigated in four patients with Bartter's syndrome treated for 12 weeks. Baseline biochemistry showed normal serum aldosterone (mean 347 pmol.l-1) and a mean serum renin of 217 mU-l-1, and a considerable increase in serum renin during captopril treatment. Serum aldosterone decreased gradually during the study period to about half its initial value. The patients presented with a mean serum potassium of 2.5 mmol.l-1, which rose to 3.4 mmol.l-1 on captopril. Lymphocytes showed a substantial captopril-induced increase in intracellular sodium (from 15 to 22.5 mmol.l-1 on average), but no change in the potassium content. Captopril was well-tolerated. It may be an alternative to potassium-sparing diuretics for maintaining normal serum potassium levels in patients with Bartter's syndrome.

Adult↗